A large scale production of the native IgM IC2 monoclonal autoantibody is under execution on contact with the Chech Rebublicbiotech company EXBIO.
News
Large scale production of the genuin native IC2 monoclonal autoantibody has been initiated on contract with the Chech Republic biotech EXBIO
Welcome to ImmunoSigns
ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.
The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.
